The researchers, after adjusting for potential confounding factors, found that RA patients who received the influenza vaccine had reduced risk of hospitalization for septicemia, bacteremia, or viremia.

The hospital preference instrumental variable had a stronger association with treatment than the other 3 instrumental variables (specialist access, calendar year, and geographic variation) during the effectiveness analyses.

The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to empagliflozin 25mg, and 123 of 4203 patients (2.9%) randomized to the placebo group.

The researchers found that over the study period (2,060,721.9 person-years), 2020 participants died, with 287 cardiovascular disease (CVD)-related deaths and 963 cancer deaths. Both low and high uric acid levels were associated with increased all-cause, CVD, and cancer mortality.

The 16-week, double-blind, placebo-controlled, multicenter, parallel-group study included 698 patients who were randomized to 3 treatment groups: 2 doses of tanezumab 2.5mg; 1 dose of tanezumab 2.5mg followed by tanezumab 5mg, or 2 doses of placebo; each injection was administered once every 8 weeks.

Although many NSAIDs must be taken every 4 hours, some come in long-acting or extended release forms. These can be taken as infrequently as once per day, which may be desirable for patients taking multiple medications.

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.

This case details complications related to tattooing in a 31-year-old woman with a history of cystic fibrosis who had undergone bilateral lung transplantation in 2009 and was on long-term immunosuppressive therapy.

The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.

When the analysis was limited to studies that examined bDMARDs vs no-treatment placebo controls, bDMARDs had a substantial benefit on physical health, measured by the Physical Component Summary, compared with mental health.

The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).